Deutsche Bank Starts Anthera Pharma (ANTH) at Buy; Risk/Reward Into VISTA-16 is Favorable

Deutsche Bank initiates coverage on Anthera Pharma (NASDAQ: ANTH) with a Buy. PT $14.00.

Deutsche analyst says, "Anthera is a small-cap biotech company w/ 2 key pipeline candidates: 1) varespladib for acute coronary syndrome (ACS) & 2) blisibimod (B-mod) for systemic lupus erythematosus (SLE). Both are lucrative opportunities. Street does not assign value to varespladib ph 3 VISTA-16 trial hitting due to high-risk nature. In our opinion, this has opened an investment opportunity. We calculate risk/reward to be very favorable at 30% down & 5x up. We apply a 30% probability of success for varespladib. This is drives our valuation."

For more ratings news on Anthera Pharma click here and for the rating history of Anthera Pharma click here.

Shares of Anthera Pharma closed at $6.35 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Anthropic CFO Krishna Rao is leading early IPO meetings with investors and has not discussed valuation - CNBC
• RBC Capital Starts Krystal Biotech (KRYS) at Outperform
• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy